
|Videos|September 8, 2017
Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer
Author(s)Jonathan Ledermann, MD
Jonathan Ledermann, MD, professor of medical oncology in the University College London Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre, discusses the toxicities associated with rucaparib (Rubraca) for the treatment of ovarian cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Gedatolisib for Advanced Breast Cancer
2
FDA Grants BTD to Sofetabart Mipitecan for Platinum-Resistant Ovarian Cancer
3
RFS Benefit Sustained at 5 Years for Intismeran Autogene in Melanoma
4
3 Trials Refine Endocrine, HER2-Targeted Therapies at SABCS
5














































